NORTH CHICAGO, ILL. — AbbVie (NYSE: ABBV) has unveiled a $195 million investment to expand its North Chicago manufacturing plant to include domestic active pharmaceutical ingredient (API) production. The expansion is part of AbbVie’s previously announced commitment to invest more than $10 billion of capital in the U.S. to support innovation and expand critical manufacturing capabilities and capacity. API manufacturing involves producing the active components responsible for the therapeutic effects of medications.
The new North Chicago API facility will expand AbbVie’s chemical synthesis capabilities in the U.S., supporting domestic production of current and next-generation neuroscience, immunology and oncology medicines. Construction of the new facility is slated to begin this fall, with the site projected to be fully operational in 2027. The project will expand AbbVie’s existing U.S. manufacturing footprint, which supports more than 6,000 American jobs across 11 manufacturing sites and thousands of additional jobs at suppliers around the U.S.
AbbVie is headquartered in North Chicago and employs more than 11,000 people in the state that work to develop and manufacture medicines for patients worldwide.